ARTICLE | Clinical News
Azedra regulatory update
August 10, 2015 7:00 AM UTC
FDA granted breakthrough therapy designation to Progenics’ Azedra to treat iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. By year end, Progenics expects to complete enroll...